Regulatory opportunities to encourage technology solutions to antibacterial drug resistance
| Autor: | Michael J. Dawson, Martin J. Blaser, David Findlay, Neil Fishman, Stuart Levy, Sarah Garner, Rick Davies, Tony White, Marcus Keogh-Brown, Ian Chopra, Lloyd Czaplewski, John H. Powers, Steven J. Projan, Richard Wise, Roger Finch, Dominique Monnet, Ragnar Norrby, Laura J. V. Piddock, Kieran Hand, Robert Guidos, Chantal M. Morel, David M. Livermore, Frances Burke, Gail Cassell, Richard Bax, Otto Carrs, Glenn Tillotson |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Microbiology (medical)
Technology Context (language use) Microbiology Orphan drug Antibiotic resistance Drug Resistance Bacterial Humans Medicine Pharmacology (medical) Available drugs Antibacterial drug Pharmacology Licensure business.industry Bacterial Infections Public relations Legislation Drug Antibacterial Drug Resistance Anti-Bacterial Agents Biotechnology Infectious Diseases Drug development Drug Design Diffusion of Innovation business |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 66:1945-1947 |
| ISSN: | 1460-2091 0305-7453 |
| Popis: | Regulatory agencies play a critical role in the licensing of new antimicrobial agents. To address the pivotal role played by regulatory agencies, particularly in the context of a paucity of new drugs active against bacteria resistant to currently available drugs, the BSAC formed the 'Urgent Need' Working Party to address the regeneration of antibacterial drug discovery and development. The Working Party identified a number of issues, including: increased application of pharmacokinetic/pharmacodynamic principles to expedite drug development; the need to prioritize licensing of drugs (including 'orphan' drugs) active in life-threatening infections; and expansion of the use of surrogate markers and rapid point of care diagnostics to facilitate drug development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|